Multiple pterygium syndromes (MPS) are a phenotypically and genetically heterogeneous group of rare Mendelian conditions characterized by multiple pterygia, scoliosis and congenital contractures of the limbs. Most often, MPS occurs as a simplex case, and of reported multiplex families, the majority consist of multiple affected siblings born to unaffected parents, consistent with inheritance in an autosomal recessive pattern 1 . In very rare instances, MPS has been transmitted from an affected parent to an affected child, indicative of autosomal dominant transmission [2] [3] [4] [5] . In 1996, we revised the classification of distal arthrogryposis (DA) syndromes and categorized several additional conditions 6 , including autosomal dominant MPS, as DA syndromes because their clinical features overlapped with DA type 1 (DA1; MIM 108120)
and Freeman-Sheldon syndrome or DA2A (MIM 193700). Autosomal dominant MPS, or DA type 8 (DA8; MIM 178110), was one of the conditions added to the DA classification based on the phenotypic features of four reported families in which pterygia, camptodactyly of the hands, vertebral fusions, and scoliosis, were transmitted from parent-to-child [2] [3] [4] [5] .
Over the past decade, three as of yet unreported families with multiple persons who had clinical characteristics consistent with the diagnosis of DA8 and evidence of parent-to-child transmission were referred to our research program on DA syndromes (Table 1 Demultiplexed BAM files were aligned to a human reference (hg19) using the BurrowsWheeler Aligner (BWA) 0.6.2. Read data from a flow-cell lane were treated independently for alignment and QC purposes in instances where the merging of data from multiple lanes was required. All aligned read data were subjected to: (1) removal of duplicate reads (Picard MarkDuplicates v1.70) (2) indel realignment (GATK IndelRealigner v1.6-11-g3b2fab9); and (3)
base quality recalibration (GATK TableRecalibration v1.6-11-g3b2fab9). Single nucleotide variant (SNV) detection and genotyping were performed using GATK UnifiedGenotyper (v1.6-11-g3b2fab9). SNV data for each sample were formatted (variant call format [VCF]) as "raw"
calls that contained individual genotype data for one or multiple samples, and flagged using the filtration walker (GATK) to mark sites that were of lower quality and potential false positives (e.g. strand bias > -0.1, quality scores (Q50), allelic imbalance (ABHet≥0.75), long homopolymer runs (HRun>3), and/or low quality by depth (QD<5).
Because DA8 is extremely rare, with only four families reported to date [2] [3] [4] [5] , we excluded SNVs with an alternative allele frequency >0.0001 in any population in the NHLBI Exome Sequencing Project Exome Variant Server (ESP6500/EVS), 1000 Genomes, or Exome Aggregation Consortium (ExAC v1.0) browser, or in an internal exome database of ~700 exomes. Additionally, SNVs that were flagged as low quality or potential false positives (quality . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not .score ≤ 30, long homopolymer run > 5, low quality by depth < 5, within a cluster of SNPs) were also excluded from analysis. Copy number variant (CNV) calls were generated from exome data Figure S1 ) and her father (Individual III-5, Figure S1 ) using the VCRome 2.1 target capture reagents (Roche Nimblegen) 19 . Sequencing was conducted on Illumina HiSeq2000 as previously described 19 . Alignment, variant calling and annotation was completed using the Mercury pipeline 20 . Comparison of exome sequence data from the proband and her affected father (Table 1 ; Figure S1 ) identified 46 shared rare variants (i.e., frequency <0.0001 in ESP6500, 1000 Genomes phase 1 (Nov 2010 release), and ExAC (October 20, 2014 release)). No variants were identified in SHPRH or SLC5A9, however, one novel variant, . All of the mutations known to cause DA1, DA2A, and DA2B 16 affect amino acid residues in the head and neck domains of embryonic myosin whereas two of the three mutations that cause DA8 occur in the tail domain. The clinical characteristics of the individuals with DA8 and a . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not .mutation in the tail domain were more similar to one another compared to the features of persons with a mutation in the head domain. This observation is limited, of course, by the small number of both families and individuals with DA8 caused by MYH3 mutations in our dataset.
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Nevertheless, speculation on domain-specific or at least domain-predominant phenotypes has been reported previously for mutations in both muscle and non-muscle myosins. For example, mutations in the head domain of MYH9 (MIM 160775) cause severe thrombocytopenia and are associated with nephritis and deafness, while mutations in the tail domain cause less severe thrombocytopenia, with median platelet counts more than two times as high as those associated with head domain mutations 22 . 23 . Moreover, mutations in the tail of MYH7 disrupt stability or self-assembly of sarcomere filaments or proteinprotein interactions mediated through the tail, whereas mutations in the motor appear to alter the ATPase and actin-binding properties of myosin 24 . This precedent of domain-specific phenotypic differences associated with mutations in other myosin genes suggest that similar genotype-phenotype relationships might exist in MYH3.
Skeletal abnormalities have not commonly been observed, or at least reported, in persons with DA1, DA2A, or DA2B and mutations in MYH3. Yet, skeletal defects were found in each of the three DA8 families with an MYH3 mutation that we studied. The most common defects observed were vertebral abnormalities including hemivertebrae and vertebral fusions of C1 and C2 or vertebrae of the thoracolumbar spine ( Figure 2) . A similar range of vertebral abnormalities has been reported previously [2] [3] [4] [5] in families with dominantly inherited MPS-as well as both carpal and tarsal fusions. In addition, two persons in Family C had craniosynostosis.
These observations suggest that embryonic myosin plays a role in skeletal development that is perturbed by the mutations in MYH3 that cause DA8. Such a role for embryonic myosin would .
not be unprecedented as other proteins of the contractile apparatus of skeletal muscle, such as troponin I type 2 (skeletal, fast) (TNNI2, MIM 191043), are expressed in osteoblasts and chondrocytes in long bone growth plates and play a role in skeletal development 25 . Moreover, multiple myosins have been reported to interact with Runx2 in rat osteoblasts and osteoblast differentiation in vitro was associated with the expression of myosin 26 .
To investigate this possibility further, we used primers specific for MYH3 cDNA that we had previously developed 27 to test for MYH3 expression in a variety of human fetal tissues. As expected, MYH3 was expressed in thymus, placenta, heart, and liver ( Figure 4A ). However, whereas MYH3 expression was not detectable in cartilage, it was expressed in bone ( Figure 4A ).
Next, to determine the relative expression levels of MYH3, we conducted a quantitative PCR assay and confirmed MYH3 expression in bone at levels comparable to several other tissues, including brain, with known MYH3 expression 28 ( Figure 4B ). These preliminary findings suggest that the bony fusions in individuals with DA8 disrupt a previously unknown role of embryonic myosin in vertebral development, and perhaps in skeletal development in general. We failed to identify the cause of dominantly inherited MPS in one family originally diagnosed with DA8 (Family D in Table 1 and Figure S1 ). In retrospect, the phenotype in this family differs from that found in the other DA8 families. Specifically, neither of the affected persons in this family had popliteal or antecubital ptergyia and both persons lacked vertebral fusions. Additionally, each individual had a ventriculoseptal defect. Accordingly, while the lack of an MYH3 mutation in this family could be interpreted as evidence that DA8 is genetically heterogeneous, the alternative is that the phenotype in this family is distinctive enough to prompt delineation of a separate Mendelian condition.
.
In summary, we used exome sequencing to discover that mutations in MYH3 cause DA8.
The phenotypic overlap among persons with DA8 coupled with physical findings distinct from other DA conditions caused by mutations in MYH3, suggests that the developmental mechanism underlying DA8 differs from other DA conditions or that certain functions of embryonic myosin may be perturbed by disruption of specific residues / domains. 
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The URLs for data presented herein are as follows: Table 1 , where there is a detailed description of the phenotype of each affected individual. A) RNA was isolated from a 17-week old fetus and cDNA was generated using standard protocols 27 . MYH3 primers were predicted to yield amplicons of 313 bp from genomic DNA ("Control") and 206 bp from cDNA. MYH3 cDNA expression was detected in bone thymus, placenta, heart, brain, and liver. Expression was not detected in cartilage, lung, and kidney. B)
Quantitative PCR was used to assess the relative expression levels of MYH3 cDNA in bone, cartilage, brain, heart, liver and lung. MYH3 cDNA levels were detected in bone at a level similar to that observed in brain and heart and was barely detectable in lung and cartilage.
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